Black Diamond Therapeutics Director Campbell Shannon Receives Stock Options

Campbell Shannon, a director of Black Diamond Therapeutics, Inc., was granted 40,000 stock options on June 26, 2026, according to a Form 4 filing. The options have an exercise price of $1.71 per share and expire on June 25, 2036. The options will vest in full upon the earlier of June 26, 2027 or the company's next annual meeting of stockholders, subject to Shannon's continued service on the vesting date. The transaction was reported as an award (Code A) and represents a direct ownership interest. The filing was signed by attorney-in-fact Brent Hatzis-Schoch on June 29, 2026. This represents a standard equity compensation award to a board member, aligning director interests with shareholder value creation through stock price appreciation.